Lancet: Can azithromycin improve prognostics in patients with new coronary pneumonia?

According to the immunomodulation effect of azithromycin, it has been proposed to treat neocycline pneumonia (COVID-19).
study aims to assess the efficacy and safety of patients with new coronary pneumonia treated with azithromycin.
This is a randomized, controlled, open-label, adaptive platform trial conducted in 176 hospitals in the UK, in which subjects were randomly divided into two groups for routine treatment or routine treatment with azithromycin (500 mg/day, oral or drips for up to 10 days or until discharge).
end of the year was 28 days of all-cause mortality.
April 27 - November 27, 2020, 16,442 patients were recruited, of whom 9,433 (57%) were compounded and 7,763 were included in the azithromycin assessment.
65.3 years (SD 15.7) and about one-third were female (38 per cent).
2,582 patients were assaillin plus conventional treatment group, and 5181 patients were assertic to simple conventional treatment group.
, 561 cases (22%) and 1162 (22%) patients in the azithromycin group and the conventional treatment group died within 28 days (ratio ratio of 0.97, 95% CI 0.87-1.07; p=0.50）。
there was no significant difference in length of hospitalization between the two groups (medium 10 days vs 11 days) and no significant difference in the proportion of patients discharged alive within 28 days (ratio 1.04, 95% CI 0.98-1.10; p=0.19）。
there was no significant difference in the proportion of patients in the two groups who did not use invasional mechanical airfly at baseline who reached the compound end point of invasional mechanical aerity or death (risk ratio 0.95, 95% CI 0.87-1.03; p=0.24）。
, for patients with new coronary pneumonia hospitalized, the addition of azithromycin to routine treatment did not improve their survival prognostics or other predetermined clinical outcomes.
use of azithromycin should be strictly limited to those with clear antimicrobial signs.